IRAP-IRAssessement of the Diagnostic Interest in Insulin Resistance of the Specific and Quantitative ELISA Assay of a Plasma Biomarker of Cellular Glucose Capture: the Secreted IRAP Protein (Regulated Amino Peptidase Insulin)
Dosage of IRAP during OGTT
Hyperinsulinism+3
+ Insulin Resistance
+ Metabolic Diseases
Diagnostic Study
Summary
Study start date: September 14, 2020
Actual date on which the first participant was enrolled.This study consists of two visits, from three to fifteen days apart. Patients with different levels of insulin resistance will be enrolled in this study. The level of insulin resistance will be estimated with a hyperinsulinemic euglycemic clamp that will be performed at the second visit. The first visit : * Subjects will be on an empty stomach * A blood test including HbA1C, C-Peptid, lipid profile, creatinine,urea, hepatic workup * An oral glucose tolerance test (OGTT) of 3 hours will be performed. Blood samples will be taken two time (T-15', T0) 15 minutes apart at Baseline (before taking the glucose). And then after the glucose intake, blood sample will be taken every 15 minutes (T15', T30', T 45', T60', T75', T90', T105', T120' and 180') to measure insulinemia, blood sugar, and IRAP concentration. The second visit includes a 3-hours hyperinsulinemic euglycemic clamp.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.21 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Diagnostic Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 40 to 65 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
Study Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 4 locations
Service de Nutrition clinique et CRNH Auvergne
Clermont-Ferrand, FranceOpen Service de Nutrition clinique et CRNH Auvergne in Google MapsInserm CIC1406, clinical research center, Grenoble Alpes university hospital
Grenoble, FranceCRNH Rhône-Alpes et Centre Hospitalier LYON Sud
Lyon, FranceEndocrinologie-Diabétologie-Nutrition et CIC, CHU DE MONTPELLIER
Montpellier, France